Deep-pocketed investors have adopted a bearish approach towards Viking Therapeutics VKTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VKTX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Viking Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 38% leaning bullish and 61% bearish. Among these notable options, 3 are puts, totaling $123,031, and 10 are calls, amounting to $1,145,550.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $90.0 for Viking Therapeutics over the recent three months.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Viking Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Viking Therapeutics's substantial trades, within a strike price spectrum from $55.0 to $90.0 over the preceding 30 days.
Viking Therapeutics 30-Day Option Volume & Interest Snapshot
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BEARISH | 01/17/25 | $32.6 | $30.6 | $30.6 | $55.00 | $306.0K | 392 | 0 |
| VKTX | CALL | TRADE | BEARISH | 01/17/25 | $23.8 | $23.0 | $23.0 | $75.00 | $230.0K | 346 | 0 |
| VKTX | CALL | TRADE | BEARISH | 01/17/25 | $22.4 | $21.0 | $21.0 | $75.00 | $210.0K | 346 | 210 |
| VKTX | CALL | TRADE | BULLISH | 01/17/25 | $17.8 | $17.4 | $17.8 | $85.00 | $176.2K | 491 | 101 |
| VKTX | CALL | SWEEP | BEARISH | 04/19/24 | $2.55 | $1.85 | $1.9 | $80.00 | $59.2K | 1.7K | 66 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Current Position of Viking Therapeutics
- With a volume of 1,621,039, the price of VKTX is down -0.87% at $75.22.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 15 days.
Expert Opinions on Viking Therapeutics
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $105.6.
- In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $90.
- An analyst from Oppenheimer has decided to maintain their Outperform rating on Viking Therapeutics, which currently sits at a price target of $138.
- An analyst from BTIG persists with their Buy rating on Viking Therapeutics, maintaining a target price of $100.
- Reflecting concerns, an analyst from Stifel lowers its rating to Buy with a new price target of $80.
- An analyst from Maxim Group downgraded its action to Buy with a price target of $120.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
